Greens Seek Greater Voice

FRANKFURT—The message from last month's national elections is that the environmental Green party can no longer be dismissed as a temporary phenomenon. But it is still too soon to know whether it can translate its electoral gains into an ability to influence government policies on scientific research. Part of that answer lies in whether the Greens join with the Social Democrats (SPD) and succeed in incorporating their views into formal opposition to the ruling coalition of Christian Democra

Written byDede Williams
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Part of that answer lies in whether the Greens join with the Social Democrats (SPD) and succeed in incorporating their views into formal opposition to the ruling coalition of Christian Democrats and Free Democrats.

The Greens captured 44 seats in the 497-seat Bundestag, up from 27 seats in the 1983 election. They received 8 percent of the popular vote, representing more than 3 million voters. The ruling coalition received 53 percent of the vote, with the SPD receiving 37 percent.

Based on their record, the Greens are likely to concentrate initially on social and environmental issues. They will undoubtedly continue to oppose new industrial technologies which, according to a party spokesman, "do little to bring about a better quality of life." That opposition extends to research involving nuclear energy, genetic engineering, information and computer systems, and much of high-energy physics, in particular laser-based technologies.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies